Paracetamol Metabolism After Liver Surgery — PETALS  

Liver Resection Clinical Trial

Official title: Observational Study Assessing Cytochrome P450 Dependant Paracetamol Metabolites Following Liver Resection.

Status Completed

Clinical Trial Summary

This observational study will assess the metabolic pathways of paracetamol that are utilised after liver resection.

Clinical Trial Description

Paracetamol is normally metabolised by the glucuronidation and sulfation of paracetamol to non toxic end products. If paracetamol is administered in supra-therapeutic doses this pathway becomes saturated and an alternative pathway is utilised. This results in a toxic metabolite called N-acetyl-p-benzoquinone imine (NAPQI). If NAPQI is not metabolised by glutathione to cysteine and mercapturic acid, then NAPQI bind to hepatic cells resulting in necrosis and hepatotoxicity.

Therefore the investigators plan to measure the levels of the paracetamol metabolites in patient undergoing liver resection.

Patients will undergo liver resection according to their onco-surgical requirements. As part of the normal post operative care they will receive 1g paracetamol every six hours unless stated otherwise by the operating surgeon. Urinary samples will be taken for the first 4 post operative days and used for analysis of the urinary paracetamol metabolite levels. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Liver Resection
• Paracetamol Administration

• NCT number: NCT01770041
• Study type: Observational
• Source: University of Edinburgh
• Status: Completed
• Phase: N/A
• Start date: February 2013
• Completion date: June 2014